Cyclacel Pharmaceuticals (CYCC) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
On January 25, 2024, Dr. Brian Schwartz, a member of the Company’s board of directors, was appointed as the interim Chief Medical Officer with immediate effect, resulting in him no longer being regarded as an independent director during his tenure.
For further insights into CYCC stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.